Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 13/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853618 | 0.84 | SLC6A4 (0.51) | OPRM1TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL374107 | 0.77 | OPRM1 (0.46) | OPRM1TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16858806 | 0.77 | LMNA (0.37) | OPRM1SLC6A2SLC6A4SLC6A3OPRL1 | |
| SCHEMBL4630111 | 0.76 | SLC6A2 (0.45) | OPRM1TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL8041537 | 0.76 | SLC6A4 (0.69) | OPRM1TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17184552 | 0.74 | KMT2A (0.31) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL13388154 | 0.74 | KDM4E (0.30) | KMT2A | |
| SCHEMBL5265848 | 0.73 | OPRM1 (0.50) | OPRM1TACR1SLC6A4 | |
| SCHEMBL7305853 | 0.73 | OPRM1 (0.45) | OPRM1TACR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27854090 | 0.72 | TACR1 (0.51) | OPRM1TACR1SLC6A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-05-27 | — | — | US | disclosed |
| WO-2008124582-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130471-A1 | Renin Inhibitors | ACE, REN, DNPEP | OPRM1 3841/4885TACR1 554/4885SLC6A2 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.